S100A1 and breast cancer: On the one hand, miR-590-5p was downregulated in breast cancer samples and could inhibit its metastasis,23 it was found that miR-590-5p levels in hepatocellular carcinoma (HCC) patients were inversely associated with tumor size, stage, epithelial–mesenchymal transition (EMT), and metastasis by targeting S100A1,24 which suggests its negative role in tumor development.